Skip to main content
Premium Trial:

Request an Annual Quote

Xenon Genetics Eyes IPO Within 18 Months

SAN FRANCISCO, Jan. 7 - Xenon Genetics, a privately held genomics-based drug-discovery company, said on Monday that it will attempt and initial public offering in 12 to 18 months.

 

The firm also said it plans to collaborate this year with a "major pharmaceutical or biotech company" in a deal similar to the research relationship it forged with Pfizer. In this arrangement, whose financial details remain undisclosed, researchers from Xenon and Pfizer's Warner-Lambert subsidiary try to uncover genomic-based targets that would increase HDL cholesterol and lower triglycerides.

 

Frank Holler, Xenon's president and CEO, would not say what those companies are. He spoke at the 20th annual JPMorgan H&Q Healthcare Conference, held here through Thursday.

 

Last month, Xenon, based in Vancouver, said it had discovered a gene related to epilepsy and one that is associated with iron metabolism regulation.

 

The epilepsy gene was found through genetic analysis of families with a form of epilepsy called idiopathic generalized epilepsy. The finding was then validated clinically in humans, according to the company.

 

The second gene was identified through an animal model and validated as an iron metabolism regulator in humans.

 

Xenon said both genes were found to be drug targets for possible therapies for treating iron disorders and epilepsy.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.